Biotech

All Articles

Bicara, Zenas look for IPOs to drive late-phase assets toward market

.Bicara Rehabs as well as Zenas Biopharma have given clean motivation to the IPO market along with f...

Genentech to shut cancer cells immunology analysis team

.Genentech will certainly shut its own cancer immunology investigation division, as well as device m...

Kezar loses strong tumor yet to prove its worth in period 1 trial

.Kezar Lifestyle Sciences is actually dropping its own unpromising period 1 sound lump medication as...

Acelyrin falls izokibep, dismisses 3rd of team

.In spite of izokibep preserving its own newfound winning touch in the medical clinic, Acelyrin is a...

Rivus' stage 2 obesity-related heart failure trial strikes endpoint

.Rivus Pharmaceuticals has plumped up the prospects of its fat-busting, muscle-sparing drug candidat...

Ovid halts preclinical job, IV course after soticlestat stop working

.Ovid Therapeutics already revealed last month that it was trimming back its head count as the provi...

Eli Lilly opens $700M nucleic acid R&ampD facility in Boston Port

.Eli Lilly has actually opened a $700 million R&ampD facility in the Boston Port, enhancing its RNA ...

Boundless Bio helps make 'reasonable' layoffs five months after $100M IPO

.Just 5 months after safeguarding a $one hundred million IPO, Vast Bio is actually actually giving u...

Halda's $126M will accelerate 'secure as well as eliminate' growth medications

.The preliminary phases of oncology R&ampD may not be except fascinating new modalities, and Halda T...

Lykos 'remorses' certainly not divulging study infractions with publisher

.Psychopharmacology has pulled three short articles regarding midstage medical trial information ana...